1st Quarter - Report

HARMONY BIOSCIENCES for HARMONY BIOSCIENCES

Period 1st Quarter 2025 Filed Apr 17, 2025 Signed by Cate McCanless

Official filing
Firm
HARMONY BIOSCIENCES
Client
HARMONY BIOSCIENCES
Income
—
Expenses
$150,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

H.R. 5547, Maintaining Investments in New Innovation (MINI) Act (118th Congress) H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act (118th Congress) H.R. 6094, Providing Realistic Opportunity To Equal and Comparable Treatment for (PROTECT) Rare Act (118th Congress) H.R. 6664, Innovation in Pediatric Drugs Act (118th Congress) H.R. 7384, Creating Hope Reauthorization Act (118th Congress) H.R. 7383, Retaining Access and Restoring Exclusivity (RARE) Act (118th Congress) H.R.7024, Tax Relief for American Families and Workers Act of 2024 (118th Congress) H.R.3433 / S.2897, Give Kids a Chance Act (118th Congress)

LobbyistCovered position, as disclosed
SUSANNA AGUIRRE HASTINGS —
CATE MCCANLESS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 7384 (119th), H.R. 5547 (119th), H.R. 6094 (119th), S. 2897 (119th), H.R. 1492 (119th), H.R. 3433 (119th), H.R. 7024 (119th), H.R. 7383 (119th), H.R. 6664 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.